May 2022 Issue Table Of Contents

From The Editor

• A New Golden Age Of Psychedelic Therapy? Proceed With Caution

Feature Articles

• A New Model For A New Era Of Psychedelic Therapy

CEO Corner

• Recognizing The Value Of Biotech Partnerships In China

Companies To Watch

• Castle Creek Biosciences

Industry Research

• Biologic And Small Molecule Drug Substance CDMO Selection Metrics Align

Industry Leader

• 5 Life Science Trends To Watch
• A Nigerian Student’s Striking Pictures Illustrate Lessons We All Must Learn

Inside The Industry

• Key Considerations In Early-Stage Biopharma Financing
• The Future Of The Life Sciences Industry And What You Need To Know
• Embracing Challenges And Executing A Successful IPO
• Is Biopharma Poised For Bigger Deals In 2022?
• Is A Key Function To Product Launch Excellence Being Overlooked?
• Patents Or Trade Secrets? How To Choose The Best IP Safeguard For R&D Assets
• Platforms To Pipelines: Part 2
• Are Cannabinoids The Next Blockbuster Drugs? A Q&A With Jazz Pharma’s CEO Bruce Cozadd

Leadership Lessons

• Tips For CEOs To Stay Healthy — Mentally And Physically — During COVID

Ask The Board

• Following The Approval Of Biogen’s Aduhelm, There Has Been Talk About “Reining In” The FDA’s Accelerated Approval Pathway. How Important Is Accelerated Approval For Rare Disease Drugs?
• How Can Digital Technology Improve The Treatment Of Neurological Disorders?
• How Can I Prepare To Join And Serve On A Board Of Directors?